5 years ago

Drug-drug interaction potential in men treated with enzalutamide: Mind the gap

D.M. Burger, D.M. Somford, A. Javad, G.E. Benoist, N.P. Erp, S. Smeenk, N. Mehra, I.M. Oort
Aim Metastatic castration resistant prostate cancer (mCRPC) patients are generally older patients with several co-morbidities and are therefore more at risk for complications due to drug-drug interactions(DDIs). We assessed the prevalence of potential DDIs in a cohort of mCRPC patients treated with enzalutamide. Methods We conducted a retrospective review of pharmacy records to retrieve individual drug histories of mCRPC patients who started enzalutamide therapy in a tertiary care setting. Potential DDIs were analyzed using two international drug interaction compendia: Lexicomp® and Micromedex®, and the Dutch drug database. Two potential pharmacodynamic DDIs were analyzed. Results 105 records were evaluated for potential DDIs with enzalutamide, 56 out of 205 different co-medications were flagged by at least one of the three compendia. Lexicomp, Micromedex and the Dutch drug database flagged for potential DDIs in 85%, 54% and 32%, respectively. 85% of DDIs were classified as major. The median number of co-medications per patient was 11(range 1–26). The median (range) number of interactions per patient was 4(0-10),1(0-5) and 0(0-2) for Lexicomp, Micromedex and the Dutch drug database, respectively. In 23% and 45% of all patients a potential DDI was found with PPIs and CNS depressants, respectively. Conclusions A high prevalence of potential DDIs was found. The inclusion and grading of potential DDIs was highly variable between the three drug interaction compendia. Physicians, nurses and pharmacists should be aware of this potential problem, which might require intensive monitoring or alternative treatment strategies to prevent suboptimal treatment of the co-morbidities in patients treated with enzalutamide.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1111/bcp.13425

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.